PMID- 35452854
OWN - NLM
STAT- MEDLINE
DCOM- 20220524
LR  - 20220524
IS  - 1873-0183 (Electronic)
IS  - 1568-9972 (Linking)
VI  - 21
IP  - 6
DP  - 2022 Jun
TI  - Performance of MPO-ANCA and PR3-ANCA immunoassays for the stratification of 
      specific ANCA-associated vasculitis: A systematic review and meta-analysis.
PG  - 103100
LID - S1568-9972(22)00070-2 [pii]
LID - 10.1016/j.autrev.2022.103100 [doi]
AB  - OBJECTIVE: To determine the impact of myeloperoxidase (MPO) and proteinase 3 
      (PR3) antigen-specific immunoassays in the stratification of patients at-risk for 
      anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) at 
      diagnosis. METHODS: A Medline search was conducted to identify diagnostic 
      accuracy studies using PR3-ANCA or MPO-ANCA for the evaluation of granulomatosis 
      with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic 
      granulomatosis with polyangiitis (EGPA). Studies estimates were pooled using the 
      bivariate method. RESULTS: Diagnostic accuracy varied by analyte and AAV subtype. 
      PR3-ANCA had greater sensitivity than MPO-ANCA for GPA (74% vs 11%, p < 0.001) 
      and MPO-ANCA greater sensitivity for MPA (73% vs 7%, p < 0.001). Specificities of 
      both MPO-ANCA and PR3-ANCA were consistently high (mean 97%, range: 93-99%) for 
      both AAV subtypes. There was insufficient data to perform meta-analysis for the 
      diagnostic accuracy of EPGA. CONCLUSION: These results validate the use of high 
      quality MPO-ANCA and PR3-ANCA immunoassays to screen patients at-risk for AAV as 
      well as to categorize disease as GPA or MPA subtype. However, caution must be 
      exercised in doing so, since some assays may not have optimal performance. Each 
      laboratory should validate appropriate algorithms based on the tests used and 
      testing population.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Walker, Brandon S
AU  - Walker BS
AD  - ARUP Laboratories, Salt Lake City, UT, United States of America.
FAU - Peterson, Lisa K
AU  - Peterson LK
AD  - ARUP Laboratories, Salt Lake City, UT, United States of America; Department of 
      Pathology, University of Utah, Salt Lake City, UT, United States of America.
FAU - Koening, Curry
AU  - Koening C
AD  - Department of Internal Medicine, Division of Rheumatology, University of Utah, 
      Salt Lake City, UT, United States of America.
FAU - White, Sandra K
AU  - White SK
AD  - Department of Pathology, University of Utah, Salt Lake City, UT, United States of 
      America.
FAU - Schmidt, Robert L
AU  - Schmidt RL
AD  - ARUP Laboratories, Salt Lake City, UT, United States of America; Department of 
      Pathology, University of Utah, Salt Lake City, UT, United States of America.
FAU - Tebo, Anne E
AU  - Tebo AE
AD  - ARUP Laboratories, Salt Lake City, UT, United States of America; Department of 
      Pathology, University of Utah, Salt Lake City, UT, United States of America. 
      Electronic address: tebo.anne@mayo.edu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20220419
PL  - Netherlands
TA  - Autoimmun Rev
JT  - Autoimmunity reviews
JID - 101128967
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - EC 3.4.21.76 (Myeloblastin)
SB  - IM
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - *Churg-Strauss Syndrome/diagnosis
MH  - *Granulomatosis with Polyangiitis/diagnosis
MH  - Humans
MH  - Immunoassay
MH  - *Microscopic Polyangiitis
MH  - Myeloblastin
MH  - Peroxidase
OTO - NOTNLM
OT  - ANCA-associated vasculitis
OT  - Anti-neutrophil cytoplasmic antibodies
OT  - Diagnostic performance
OT  - Immunoassay
OT  - Myeloperoxidase
OT  - Proteinase 3
OT  - Sensitivity
OT  - Specificity
EDAT- 2022/04/23 06:00
MHDA- 2022/05/25 06:00
CRDT- 2022/04/22 20:10
PHST- 2022/03/26 00:00 [received]
PHST- 2022/04/18 00:00 [accepted]
PHST- 2022/04/23 06:00 [pubmed]
PHST- 2022/05/25 06:00 [medline]
PHST- 2022/04/22 20:10 [entrez]
AID - S1568-9972(22)00070-2 [pii]
AID - 10.1016/j.autrev.2022.103100 [doi]
PST - ppublish
SO  - Autoimmun Rev. 2022 Jun;21(6):103100. doi: 10.1016/j.autrev.2022.103100. Epub 
      2022 Apr 19.